By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market Tuesday that its fourth quarter sales grew 17 percent or 11 percent organically.

For the quarter ended Dec. 31, 2011, the molecular diagnostics firm generated sales of $334.4 million, up from $286 million a year ago, surpassing analyst estimates of $323.3 million.

The acquisitions of Cellestis and Ipsogen provided 6 percentage points to growth, the company said, adding that currency had no effect on sales growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.